 Patients with granulomatosis with polyangiitis GPA, Wegeners will be recruited at one of the Vasculitis Centers of Excellence. Participants will be randomized 1:1 either to taper their prednisone dose down to 5 mgday according to a standardized schedule and stay at 5 mgday of prednisone for the duration of the study or until a study endpoint, or taper their prednisone dose down to 0 mgday using a standard schedule and stay at 0 mgday for the duration of the study or until a study endpoint. All study participants will be followed for 6 months from reaching a prednisone dose of 5 mgday or until an increase of prednisone dose after randomization occurs, whichever comes first. 